Patents by Inventor Aron David THALL

Aron David THALL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-L1 ANTAGONIST COMBINATION TREATMENTS
    Publication number: 20210069326
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • PD-L1 antagonist combination treatments
    Patent number: 10869924
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 22, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, Adrian Woolfson
  • COMBINATION OF AN OX40 AGONIST AND A 4-1BB AGONIST MONOCLONAL ANTIBODY FOR TREATING CANCER
    Publication number: 20190031765
    Abstract: The present disclosure describes combination therapies comprising an agonist of OX40 and an agonist of 4-1BB, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: January 31, 2019
    Applicant: PFIZER INC.
    Inventors: HUA LONG, ARON DAVID THALL
  • PD-L1 Antagonist Combination Treatments
    Publication number: 20180169232
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON